Cezary Kępka

Cezary Kępka

Auto-generated profile, based on publicly available information

Cezary Kępka

Department of Coronary and Structural Heart Diseases, Cardinal Stefan Wyszynski Institute of Cardiology, 04-628 Warsaw, Poland

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2021 in JACC: Cardiovascular Imaging
Verified
Journal Article
Closed access
JHJan Henzel
Jan Henzel
CKCezary Kępka
Cezary Kępka
MKMariusz Kruk
Mariusz Kruk
MMMagdalena Makarewicz-Wujec
Magdalena Makarewicz-Wujec
ŁWŁukasz Wardziak
Łukasz Wardziak
MDMarcin Demkow
Marcin Demkow

1 January 2019 in Journal of Cardiovascular Computed Tomography
Verified
Journal Article
Closed access
ŁWŁukasz Wardziak
Łukasz Wardziak
MKMariusz Kruk
Mariusz Kruk
WPWeronika Pleban
Weronika Pleban
MDMarcin Demkow
Marcin Demkow
WRWitold Rużyłło
Witold Rużyłło
CKCezary Kępka
Cezary Kępka

1 September 2017 in Journal of Cardiovascular Computed Tomography
Verified
Journal Article
Closed access
MSMateusz Solecki
Mateusz Solecki
MKMariusz Kruk
Mariusz Kruk
MDMarcin Demkow
Marcin Demkow
USU. Joseph Schoepf
U. Joseph Schoepf
MRMichael A. Reynolds
Michael A. Reynolds
CKCezary Kępka
Cezary Kępka

30 August 2021 in Nutrients
Verified
Journal Article
Open access
PDF file
MMMagdalena Makarewicz-Wujec
Magdalena Makarewicz-Wujec
JHJan Henzel
Jan Henzel
CKCezary Kępka
Cezary Kępka
MKMariusz Kruk
Mariusz Kruk
ŁWŁukasz Wardziak
Łukasz Wardziak
MKMałgorzata Kozłowska-Wojciechowska
Małgorzata Kozłowska-Wojciechowska
Monocyte chemotactic protein-1 (MCP-1) plays an important role in the entire atherosclerotic process, from atherogenesis to destabilisation of the atherosclerotic plaque. The purpose of this study is to evaluate the effect of the dietary approaches to stop hypertension (DASH) diet in patients with coronary artery disease on the MCP-1 plasma concentration and to evaluate the potential usefulness of this chemokine as a marker of change in the volume and composition of coronary plaque. Material and method. As part of the dietary intervention to stop coronary atherosclerosis in computed tomography (DISCO-CT) study, patients were randomised to an intervention group (n = 40) in which the DASH diet was introduced, and to a control group (n = 39) with no dietary intervention. In the DASH group, dietary counselling was provided at all follow-up visits within 12 months of the follow-up period. MCP-1 plasma concentration was determined using enzyme-linked immunosorbent assay (ELISA). Coronary plaque analysis was performed using a semi-automated plaque analysis software system (QAngioCT, Medis, The Netherlands). Results. In the DASH group, MCP-1 plasma concentration significantly decreased by 34.1 pg/mL (p = 0.01), while in the control group, the change in MPC-1 was not significant. Significant inverse correlations were revealed for the change in MCP-1 plasma concentration and change in the consumption of vitamin C and dietary fibre both in the DASH (r = −0.519, p = 0.0005; r = −0.353, p = 0.025, respectively) and in the control group (r = −0.488 p = 0.001; r = −0.502, p = 0.001, respectively). In patients with the highest decrease in percent atheroma volume (PAV), a significant positive correlation was observed between the change in MCP-1 plasma concentration and changes in PAV (r = 0.428, p = 0.033) and calcified plaque component (r = 0.468, p = 0.018), while the change in noncalcified plaque component correlated inversely with change in MCP1 (r = −0.459, p = 0.021). Conclusion. Dietary intervention based on the DASH diet model reduces the MCP-1plasma concentration, mostly due to an increased intake of plant-derived, fibre-rich foods and antioxidants. The change in MCP-1 plasma concentration seems to reflect changes in the atheroma volume and proportions between the calcified and non-calcified plaque elements.

MFMichal Miroslaw Farkowski
Michal Miroslaw Farkowski
KLKrzysztof Lach
Krzysztof Lach
MPMalwina Pietrzyk
Malwina Pietrzyk
EBEwelina Baryla-Zapala
Ewelina Baryla-Zapala
MGMałgorzata Gałązka-Sobotka
Małgorzata Gałązka-Sobotka
THTomasz Hryniewiecki
Tomasz Hryniewiecki
Hospital-based health technology assessment (HB-HTA) is a scientific approach to inform decisions on investments in health technologies across multiple medical specialties at a hospital level. HB-HTA is not currently practiced in Poland. This study aimed to assess the need for HTA in Polish hospitals, including perceived benefits and challenges of adoption of HB-HTA in Poland, expected demand for training in HB-HTA, and perception of incentives to foster HB-HTA adoption. Study data were gathered using the computer-assisted telephone interview (CATI) technique. Between June and August 2021, 50 interviews were conducted: 52% of respondents had over 10 years of experience, and 40% comprised the highest degree reference hospitals. A high or moderate need for HB-HTA was reported by 86% of managers. The ability to indicate valuable and affordable medical technologies was the main reported benefit of HB-HTA (90%). The main obstacle to the adoption of HB-HTA was the shortage of competent staff (84%). The most important incentives to adopt HB-HTA were free training and premium financing from the National Health Fund. There is a clear need for HB-HTA in Polish hospitals despite some important obstacles.

1 September 2016 in EuroIntervention
Verified
Journal Article
Closed access
RPRadoslaw Pracon
Radoslaw Pracon
RGRoman Grygoruk
Roman Grygoruk
ZDZofia Dzielinska
Zofia Dzielinska
CKCezary Kepka
Cezary Kepka
ADAgnieszka Dąbrowska
Agnieszka Dąbrowska
MDMarcin Demkow
Marcin Demkow
The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)